ECO Animal Health Group's (EAH) "Buy" Rating Reaffirmed at Shore Capital

Key Points

• Shore Capital has reaffirmed a "buy" rating for ECO Animal Health Group (EAH) with a target price of GBX 150, suggesting a potential upside of 94.49% from its last closing price.
• Currently, ECO Animal Health Group's stock trades at GBX 77.13, with a market capitalization of £52.05 million and a significant debt-to-equity ratio of 4.81.
• The company specializes in veterinary pharmaceuticals, particularly in developing solutions for pigs and poultry, notably with their lead product Aivlosin®.

ECO Animal Health Group (LON:EAH - Get Free Report)'s stock had its "buy" rating restated by Shore Capital in a research note issued to investors on Monday,Digital Look reports. They presently have a GBX 150 target price on the stock. Shore Capital's price target would indicate a potential upside of 94.49% from the stock's previous close.

ECO Animal Health Group Price Performance

Shares of EAH stock opened at GBX 77.13 on Monday. The stock has a 50 day moving average of GBX 81.76 and a two-hundred day moving average of GBX 69.73. The company has a current ratio of 2.96, a quick ratio of 2.14 and a debt-to-equity ratio of 4.81. ECO Animal Health Group has a 12 month low of GBX 50 and a 12 month high of GBX 100. The company has a market capitalization of £52.05 million, a P/E ratio of 31.74 and a beta of -0.05.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline. Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide. Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.